Our website uses cookies to enhance and personalize your experience and to display advertisements (if any). Our website may also include third party cookies such as Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click the button to view our Privacy Policy.

Advances in cryo-electron microscopy illuminate immune sensor mechanisms

Advances in cryo-electron microscopy illuminate immune sensor mechanisms
Contents
  1. What inflammasomes and PANoptosomes are
  2. How the main sensors switch on
  3. The current state of pharmaceutical research
  4. What remains unknown
  5. References

A review by four immunologists at St. Jude Children’s Research Hospital, published in Cell Research on Sept. 4, 2026, explains how innate immune sensors assemble into inflammasomes and PANoptosomes, the protein complexes that set off inflammation and inflammatory cell death. Its main conclusions are that cryo-electron microscopy has shown how several sensors switch from a resting to an active form, that most drug candidates so far target a single sensor, NLRP3, and that no complete structure of an assembled inflammasome or PANoptosome has yet been solved.

The authors, Saurabh Upadhyay, Raghavendra Nagampalli, Sara Resende and Thirumala-Devi Kanneganti, summarize published research rather than report a new experiment. The article is open access.

What inflammasomes and PANoptosomes are

Inflammasomes function as protein assemblies responsible for triggering the enzyme caspase-1. Subsequently, caspase-1 processes a pair of inflammatory signaling molecules, namely IL-1β and IL-18, while simultaneously cleaving the gasdermin D protein to generate membrane pores within the cell.

PANoptosomes drive PANoptosis, an inflammatory form of cell death that combines features of pyroptosis, apoptosis and necroptosis. Inflammasomes can be part of them, and they also release other signals such as TNF and interferons. The sensors the review places in PANoptosomes include ZBP1, AIM2, RIPK1, NLRP3, NLRP1, NLRC5 and NLRP12.

Scientists identify a mysterious quasi-moon close to Earth

How the main sensors switch on

NLRP3 remains confined within a cage-shaped assembly until the NEK7 protein attaches to it. Subsequently, it reshapes into a disk-like structure that extends filaments to gather the ASC adaptor protein. Conversely, AIM2 becomes active upon recognizing double-stranded DNA, a process that alleviates its autoinhibition.

SensorWhat activates or restrains itConditions the review links to it
NLRP3Activated after NEK7 binds to itCryopyrin-associated periodic syndromes (CAPS); Alzheimer’s and Parkinson’s disease
NLRP1Kept inactive by the enzyme DPP9 until a released fragment forms filamentsSkin and autoimmune conditions; traumatic brain injury
NAIP/NLRC4NAIP detects bacterial proteins such as flagellin and assembles NLRC4Enterocolitis caused by gain-of-function mutations
PyrinActivation depends on phosphorylation regulated by Rho GTPases and on 14-3-3 proteinsFamilial Mediterranean fever (FMF)

The review also connects these pathways to infections, which they help fight and which pathogens try to suppress, and to obesity, diabetes, gout and cardiovascular and kidney disease. In cancer their role depends on the context, with studies reporting both tumor-promoting and tumor-suppressing effects.

The current state of pharmaceutical research

Most candidates target NLRP3. MCC950, the best-known inhibitor, holds the sensor in its inactive shape, but its clinical development has been limited by off-target toxicity and by its failure to block some CAPS-causing variants. Other NLRP3 agents include CY-09, dapansutrile (OLT1177) and molecules that degrade NEK7, and the review notes that some have reached clinical evaluation.

Further down the pathway, the review covers blocking caspase-1 and gasdermin D. For FMF, colchicine remains the most widely used treatment, although it does not act specifically on Pyrin. The authors suggest that targeting individual sensors, rather than shared parts such as ASC or caspase-1, could make treatments more precise, and they name IL-1β, IL-18, C-reactive protein and ferritin as possible markers of disease activity.

Billion-dollar companies that will make their mark in 2024

What remains unknown

There is still no atomic-resolution structure of a fully assembled inflammasome or PANoptosome, and many proposed PANoptosome architectures are inferred from genetic, biochemical and imaging data. NLRC5 and NLRP12 are known only at the level of individual domains, and Pyrin’s full architecture is unresolved. Most structural studies also used a single trigger, which may not reflect the body, where several signals arrive at once.

References

By Hugo Carrasco

You may also like